We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Vida Demarin (International Institute for Brain Health, Zagreb, Croatia) kindly took the time to speak with us on the topic of the debate session she participated in: Should statins be given to people over age 80 for stroke prevention? As co-Chair of CONy 2021, she also shared her excitement for the next congress, which will be […]
We were delighted to talk to Ingrid Scheffer (The University of Melbourne, The Royal Children’s Hospital and Austin Health, Victoria, Australia) regarding the open-label extension study of fenfluramine in patients with Dravet syndrome (Clinical Trial Identifier: NCT02823145). The abstract ‘Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine Hydrochloride) in an Open-Label Extension Study of Dravet Syndrome […]
We caught up with Kelly Knupp (University of Colorado, Anschutz Medical Campus, Children’s Hospital Colorado, CO, USA) to discuss the use of fenfluramine for the reduction of seizures associated with Lennox-Gastaut syndrome. (Clinical Trial Identifier: NCT03355209). The abstract ‘Efficacy and safety of FINTEPLA (fenfluramine) for the treatment of seizures associated with Lennox-Gastaut syndrome: a randomized, […]
We were delighted to have an opportunity to hear all about the Stroke Action Plan for Europe from Arlene Wilkie, Director General of the Stroke Alliance for Europe (SAFE). Related useful resources: Stroke Alliance for Europe (SAFE) Economic Impact of Stroke in Europe Questions What are the major challenges in stroke care across Europe and […]
We were delighted to have the opportunity to speak with Indu Subramanian (Geffen School of Medicine, UCLA, and West Los Angeles Veterans Administration, Los Angeles, CA, USA) around the focus of her recently published article entitled: Synergy of pandemics-social isolation is associated with worsened Parkinson severity and quality of life, which was highlighted as a top […]
It was an honour to speak with Ludwig Kappos (University Hospital Basel, University of Basel, Basel, Switzerland) around his presentation, a sub analysis of the OPTIMUM study (ClinicalTrials.gov identifier: NCT02425644), entitled: P0071 – Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study. Questions […]
We were delighted to speak with Ludwig Kappos (University Hospital Basel, University of Basel, Basel, Switzerland) about his highlights from the MSVirtual2020 meeting. Disclosures: Dr Kappos reports receiving grants from Actelion, Allergan, Almirall, Baxalta, Bayer Healthcare, Biogen, CSL Behring, Desitin, Eisai, Excemed, Genzyme, INNO Swiss, Japan Tabacco, Merck, Novartis, Roche, Pfizer, Receptos, Sanofi, Santhera and […]
Get the latest clinical insights from touchNEUROLOGY